Get National Cancer Institute Clinical Data Reporting Form - Lung 2008-2024

The NCI-60 cancer cell line panel is a group of 60 human cancer cell lines used by the National Cancer Institute (NCI) for the screening of compounds to detect potential anticancer activity.

On August 9, 2023, the Food and Drug Administration granted regular approval to pralsetinib (Gavreto, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Cancer Therapy Evaluation Program (CTEP)

Clinical Trials Monitoring Branch (CTMB)

NRG Oncology is a non-profit research organization. It brings together the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG)—each recognized internationally as a research leader.

Access CTEP-IAM https://ctepcore.nci.nih.gov/iam/ • Select “Request New Account”. Answer the “Have you ever registered with CTEP?” question by selecting “Yes” and “Proceed”. Enter your < CTEP Person ID >, < First Name >, and < Last Name > (check your registration notification email) and select “Continue”.

CTEP plans, reviews, and coordinates clinical trials for investigational anticancer agents, from the inception of protocols through the preparation and submission of Investigational New Drug Applications (INDs) to the Food and Drug Administration (FDA).

The targeted therapy Osimertinib (Tagrisso) was approved by the FDA in 2021 to be given after surgery—that is, as adjuvant therapy—to people with early-stage NSCLC that has certain mutations in the EGFR gene.